You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Axsome

Showing 1 - 25 of 25
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Insomnia Trial in Philadelphia (drug, behavioral, other)

Not yet recruiting
  • Insomnia
  • Solriamfetol 75 MG
  • +3 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania, Behavioral Sleep Medicine Program
Apr 28, 2023

Excessive Sleepiness, Shift-work Disorder Trial in Boston (Solriamfetol Oral Tablet, Placebo)

Recruiting
  • Excessive Sleepiness
  • Shift-work Disorder
  • Solriamfetol Oral Tablet
  • Placebo
  • Boston, Massachusetts
    Brigham and Women's Hospital
May 23, 2022

Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer, Agitation,Psychomotor Trial in Australia, United States

Completed
  • Agitation in Patients With Dementia of the Alzheimer's Type
  • +2 more
  • Phoenix, Arizona
  • +61 more
Oct 7, 2020

MDD, Treatment Resistant Depression Trial in New York (AXS-05, Bupropion SR)

Enrolling by invitation
  • Major Depressive Disorder
  • Treatment Resistant Depression
  • New York, New York
    Axsome Research Site
Jul 20, 2021

Smoking Cessation, Smoking, Cigarette, Nicotine Dependence Trial in Durham (AXS-05, Bupropion SR)

Completed
  • Smoking Cessation
  • +2 more
  • Durham, North Carolina
    Duke Center for Smoking Cessation
Mar 17, 2020

ADHD Trial in United States (Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo)

Recruiting
  • ADHD
  • Solriamfetol 150 mg
  • +2 more
  • Orlando, Florida
  • +5 more
Jul 25, 2023

Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer, Agitation Trial in United States (AXS-05, Placebo)

Recruiting
  • Agitation in Patients With Dementia of the Alzheimer's Type
  • +2 more
  • Peoria, Arizona
  • +22 more
Dec 12, 2022

Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer, Agitation, Psychomotor Trial in United States (AXS-05

Enrolling by invitation
  • Agitation in Patients With Dementia of the Alzheimer's Type
  • +2 more
  • AXS-05 (dextromethorphan-bupropion)
  • Lafayette, California
  • +26 more
Sep 29, 2022

Migraine Trial in United States (AXS-07 (meloxicam-rizatriptan))

Recruiting
  • Migraine
  • AXS-07 (meloxicam-rizatriptan)
  • Colton, California
  • +18 more
Sep 19, 2022

Narcolepsy, Cataplexy, Excessive Daytime Sleepiness Trial in Canada, United States (AXS-12 (reboxetine), Placebo)

Enrolling by invitation
  • Narcolepsy
  • +2 more
  • AXS-12 (reboxetine)
  • Placebo
  • Santa Ana, California
  • +18 more
Sep 23, 2022

Narcolepsy, Cataplexy, Excessive Daytime Sleepiness Trial in Canada, United States (AXS-12 (reboxetine), Placebo)

Recruiting
  • Narcolepsy
  • +2 more
  • AXS-12 (reboxetine)
  • Placebo
  • Alabaster, Alabama
  • +45 more
Sep 23, 2022

Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer, Agitation,Psychomotor Trial in Canada, United States

Completed
  • Agitation in Patients With Dementia of the Alzheimer's Type
  • +2 more
  • Sun City, Arizona
  • +62 more
Dec 13, 2022

MDD, Treatment Resistant Depression, Depression Trial in United States (AXS-05)

Completed
Has Results
  • Major Depressive Disorder
  • +2 more
  • AXS-05 (dextromethorphan and bupropion) oral tablets
  • Phoenix, Arizona
  • +50 more
Sep 16, 2022

Treatment Resistant Depression, MDD Trial in United States (AXS-05, Placebo)

Completed
  • Treatment Resistant Depression
  • Major Depressive Disorder
  • Little Rock, Arkansas
  • +19 more
Jul 8, 2022

Treatment Resistant Depression, MDD Trial in United States (AXS-05 (dextromethorphan-bupropion))

Completed
  • Treatment Resistant Depression
  • Major Depressive Disorder
  • AXS-05 (dextromethorphan-bupropion)
  • Little Rock, Arkansas
  • +19 more
Jun 2, 2022

Excessive Daytime Somnolence, Obstructive Sleep Apnea Trial in Worldwide (Solriamfetol, Placebo)

Active, not recruiting
  • Excessive Daytime Somnolence
  • Obstructive Sleep Apnea
  • Los Angeles, California
  • +27 more
May 31, 2022

Depression, MDD Trial in United States (AXS-05, Placebo)

Completed
  • Depression
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +42 more
Sep 22, 2021

MDD Trial in United States (AXS-05, Bupropion)

Completed
Has Results
  • Major Depressive Disorder
  • Beverly Hills, California
  • +3 more
Sep 22, 2021

Migraine Trial in United States (AXS-07)

Completed
  • Migraine
  • Birmingham, Alabama
  • +50 more
Sep 14, 2021

Migraine Trial in United States (AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo)

Completed
  • Migraine
  • AXS-07 (MoSEIC meloxicam and rizatriptan)
  • Placebo
  • Birmingham, Alabama
  • +40 more
Apr 28, 2021

Migraine Trial in United States (AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan)

Completed
  • Migraine
  • AXS-07 (MoSEIC meloxicam and rizatriptan)
  • +3 more
  • Birmingham, Alabama
  • +84 more
Apr 22, 2021

Treatment Resistant MDD Trial in United States (AXS-05, Bupropion)

Completed
  • Treatment Resistant Major Depressive Disorder
  • Phoenix, Arizona
  • +73 more
Mar 22, 2021

Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness Trial in United States (AXS-12 (Reboxetine), Placebo)

Completed
  • Narcolepsy
  • +2 more
  • AXS-12 (Reboxetine)
  • Placebo
  • Birmingham, Alabama
  • +13 more
Dec 8, 2020

Osteoarthritis, Knee Trial in Australia, United States (AXS-02, Placebo)

Unknown status
  • Osteoarthritis, Knee
  • Birmingham, Alabama
  • +60 more
Jan 8, 2019

Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy Trial in Worldwide (AXS-02 (oral zoledronate), Placebo)

Unknown status
  • Complex Regional Pain Syndrome
  • Reflex Sympathetic Dystrophy
  • AXS-02 (oral zoledronate)
  • Placebo
  • Tucson, Arizona
  • +43 more
Mar 21, 2018